Phenylglycinamide Derivatives Selective Factor VIIa Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current factor VIIa inhibitors for treating thromboembolic disorders have limitations in selectivity, pharmacological characteristics, and efficacy, particularly in inhibiting factor VIIa and plasma kallikrein, and there is a need for improved compounds with enhanced antithrombotic effects and reduced bleeding liability.
Innovation Solution
Development of novel phenylglycinamide and pyridylglycinamide derivatives and their analogues as selective inhibitors of serine protease enzymes, including factor VIIa and plasma kallikrein, with optimized pharmacokinetic and pharmaceutical properties to treat thromboembolic disorders and inflammatory conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current factor VIIa inhibitors are used to treat thromboembolic disorders, then antithrombotic effects are achieved, but selectivity and efficacy are limited along with bleeding liability
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of factor VIIa inhibitors through systematic variation of substituents at specific positions (R1-R10) on the phenylglycinamide and pyridylglycinamide cores. This structural optimization enables differentiation between factor VIIa and plasma kallikrein binding, achieving high selectivity (IC50 ratio >100:1) while maintaining antithrombotic efficacy and reducing bleeding liability through improved pharmacological characteristics
2Productivity
If factor VIIa inhibitors are developed to inhibit both factor VIIa and plasma kallikrein, then antithrombotic efficacy is improved, but selectivity among serine proteases becomes challenging
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at defined positions on the glycinamide scaffold to create localized interaction zones that differentiate between factor VIIa and plasma kallikrein binding sites. The substituted phenyl or pyridyl ring at position Z and specific substituents R1-R4 create localized chemical environments that enhance selectivity while maintaining dual inhibitory activity
Solution Approach 2:
The patent systematically varies chemical parameters including substituent types (halogen, alkyl, alkoxy, nitro, cyano), their positions, and stereochemistry to optimize the balance between inhibiting factor VIIa and plasma kallikrein. This parameter optimization achieves compounds with IC50 ratios >100:1 for factor VIIa versus plasma kallikrein while maintaining therapeutic efficacy
3Reliability
If novel phenylglycinamide and pyridylglycinamide derivatives are designed for enhanced selectivity, then inhibition of factor VIIa and plasma kallikrein is improved, but pharmacokinetic properties require optimization
Solution Approach 1:
The patent applies parameter changes by modifying physicochemical properties of the inhibitor molecules through substituent selection (affecting molecular weight, lipophilicity, hydrogen bonding capacity) to optimize pharmacokinetic parameters including oral bioavailability, plasma protein binding, metabolic stability, and half-life while maintaining high selectivity for factor VIIa and plasma kallikrein inhibition
Data Source
AI summary
The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV):or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.